What place for the new biologics in the treatment of necrotising vasculitides

Clinical and Experimental Rheumatology

Volumn 24, Issue 2 SUPPL. 41, 2006, Pages

  Jayne, David ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

ANCA; Anti TNF ; Biologic agents; Rituximab; Vasculitis; Vasculitis treatment

Indexed keywords

ALEMTUZUMAB; ANTIBODY; BIOLOGICAL FACTOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ETANERCEPT; IMMUNOGLOBULIN; INFLIXIMAB; INTERLEUKIN 6 ANTIBODY; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; PLACEBO; POLYCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANAPHYLACTOID PURPURA; AORTA ARCH SYNDROME; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; DRUG INDICATION; EDITORIAL; HUMAN; HYPOGAMMAGLOBULINEMIA; IMMUNE DEFICIENCY; INFECTION; LONG TERM CARE; LYMPHOCYTE DEPLETION; MICROSCOPIC POLYANGIITIS; NECROTIZING ARTERITIS; NONHUMAN; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; WEGENER GRANULOMATOSIS;

BIOLOGICAL PRODUCTS; COST-BENEFIT ANALYSIS; CYTOKINES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; LYMPHOCYTE DEPLETION; NECROSIS; REMISSION INDUCTION; VASCULITIS;

EID: 33745698612     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (65)

1. HOFFMAN GS, KERR GS, LEAVITT RY et al.: Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992; 116: 488-98.
2. RASMUSSEN N: European therapeutic trials in ANCA-associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials. Clinical and Experimental Immunology. 1995; 101 (Suppl. 1): 29-34.
3. GUILLEVIN L, LHOTE F, GAYRAUD M et al.: Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore). 1996; 75: 17-28.
4. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med. 2005; 352: 351-61.
5. JAYNE DR, LOCKWOOD CM: High-dose pooled immunoglobulin in the therapy of systemic vasculitis/par. Trans Assoc Am Physicians/par. 1991;104/par: 304-12.
6. JAYNE DR, DAVIES MJ, FOX CJ et al.: Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet. 1991; 337: 1137-9.
7. MATHIESON PW, COBBOLD SP, HALE G et al.: Monoclonal-antibody therapy in systemic vasculitis. N Engl J Med. 1990; 323: 250-254.
8. ABE J, JIBIKI T, NOMA S et al.: Gene expression profiling of the effect of high-dose intravenous Ig in patients with Kawasaki disease. J Immunol. 2005; 174: 5837-45.
9. JAYNE D, RASMUSSEN N, ANDRASSY K et al.: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003; 349: 36-44.
10. BOOTH AD, ALMOND MK, BURNS A et al.: Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis. 2003; 41: 776-84.
11. REINHOLD-KELLER E, HERLYN K, WAGNER-BASTMEYER R et al.: Effect of Wegener's granulomatosis on work disability, need for medical care, and quality of life in patients younger than 40 years at diagnosis. Arthritis Rheum. 2002; 47: 320-5.
12. KOUTANTJI M, HARROLD E, LANE SE et al.: Investigation of quality of life, mood, pain, disability, and disease status in primary systemic vasculitis. Arthritis Rheum. 2003; 49: 826-37.
13. NEWBURGER JW, TAKAHASHI M, BURNS JC et al.: The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986; 315: 341-7.
14. KAZATCHKINE M, MOUTHON L, KAVERI SV: Immunomodulatory effects of intravenous immunoglobulins. Ann Med Interne (Paris). 2000; 151 (Suppl.1): 1S13-1S18.
15. BELLISAI F, MOROZZI G, MARCOLONGO R, GALEAZZI M: Pregnancy in Wegener's granulomatosis: successful treatment with intravenous immunoglobulin. Clin Rheumatol. 2004; 23: 533-5.
16. JAYNE DR, LOCKWOOD CM: Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol. 1996; 35: 1150-3.
17. ITO-IHARA T, ONO T, NOGAKI F et al.: Clinical efficacy of intravenous immunoglobulin for patients with MPO-ANCA-associated rapidly progressive glomerulonephritis. Nephron Clin Pract. 2006; 102: c35-c42.
18. JAYNE DR, CHAPEL H, ADU D et al.: Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. Q J Med. 2000; 93: 433-9.
19. LEVY Y, UZIEL Y, ZANDMAN GG et al.: Intravenous immunoglobulins in peripheral neuropathy associated with vasculitis. Ann Rheum Dis. 2003; 62: 1221-3.
20. DANIELI MG, CAPPELLI M, MALCANGI G et al.: Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome. Ann Rheum Dis. 2004; 63: 1649-54.
21. SCHMITT WH, HAGEN EC, NEUMANN I et al.: Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int. 2004; 65: 1440-8.
22. LOCKWOOD CM, THIRU S, ISAACS JD et al.: Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet. 1993; 341: 1620-2.
23. LOCKWOOD CM, HALE G, WALDMAN H, JAYNE DR: Remission induction in Behcet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. Rheumatology (Oxford). 2003.
24. SPECKS U, FERVENZA FC, McDONALD TJ, HOGAN MC: Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum. 2001; 44: 2836-40.
25. TAKEMURA S, KLIMIUK PA, BRAUN A et al.: T cell activation in rheumatoid synovium is B cell dependent. J Immunol. 2001; 167: 4710-8.
26. ZHU LP, CUPPS TR, WHALEN G, FAUCI AS: Selective effects of cyclophosphamide therapy on activation, proliferation, and differentiation of human B cells. J Clin Invest. 1987; 79: 1082-90.
27. VOSWINKEL J, MUELLER A, KRAEMER JA et al.: B lymphocyte maturation in Wegener's granulomatosis: a comparative analysis of VH genes from endonasal lesions. Ann Rheum Dis. 2005.
28. SANDERS JS, HUITEMA MG, KALLENBERG CG, STEGEMAN CA: Plasma levels of soluble IL-2R, soluble CD30, IL-10 and BAFF during follow-up in PR3-ANCA-associated vasculitis: associations with disease activity and relapse. Ann Rheum Dis. 2006.
29. GONG Q, OU Q, YE S et al.: Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol. 2005; 174: 817-26.
30. KOUKOULAKI M, SMITH KG, JAYNE DR: Rituximab in Churg-Strauss syndrome. Ann Rheum Dis. 2006; 65: 557-9.
31. KALLENBACH M, DUAN H, RING T: Rituximab induced remission in a patient with Wegener's granulomatosis. Nephron Clin Pract. 2005; 99: c92-c96.
32. FERRARO AJ, DAY CJ, DRAYSON MT, SAVAGE CO: Effective therapeutic use of rituximab in refractory Wegener's granulomatosis. Nephrol Dial Transplant. 2005; 20: 622-5.
33. KOUKOULAKI M, ABEYGUNASEKARA SC, SMITH KG, JAYNE DR: Remission of refractory hepatitis C-negative cryoglobulinaemic vasculitis after rituximab and infliximab. Nephrol Dial Transplant. 2005; 20: 213-6.
34. BHATIA A, ELL PJ, EDWARDS JC: Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis. 2005; 64: 1099-100.
35. ERIKSSON P: Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med. 2005; 257: 540-8.
36. BACHMEYER C, CADRANEL JF, DEMONTIS R: Rituximab is an alternative in a case of contra-indication of cyclophosphamide in Wegener's granulomatosis. Nephrol Dial Transplant. 2005; 20: 1274.
37. KEOGH KA, YTTERBERG SR, FERVENZA FC et al.: Rituximab for Refractory Wegener's Granulomatosis: Report of A Prospective, Open-Label Pilot Trial. Am J Respir Crit Care Med. 2005.
38. CHEUNG CM, MURRAY PI, SAVAGE CO: Successful treatment of Wegener's granulomatosis associated scleritis with rituximab. Br J Ophthalmol. 2005; 89: 1542.
39. MEMET B, RUDINSKAYA A, KREBS T, OELBERG D: Wegener granulomatosis with massive intracerebral hemorrhage: remission of disease in response to rituximab. J Clin Rheumatol. 2005; 11: 314-8.
40. ARIES PM, HELLMICH B, BOTH M et al.: Lack of efficacy of Rituximab in Wegener's Granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis. 2005.
41. ZAJA F, DE VITA S, MAZZARO C et al.: Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood. 2003; 101: 3827-34.
42. SMITH KG, JAYNE DRW: B-Cell depletion with rituximab in refractory vasculitis. Kidney & Blood Pressure Research. 2003; 26: 294.
43. RADFORD DJ, LORD JM, SAVAGE COS: The activation of the neutrophil respiratory burst by anti-neutrophil cytoplasm autoantibody (ANCA) from patients with systemic vasculitis requires tyrosine kinases and protein kinase C activation. Clinical & Experimental Immunology. 1999; 118: 171-9.
44. EWERT BH, JENNETTE JC, FALK RJ: Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells. Kidney Int. 1992; 41: 375-83.
45. LITTLE MA, BHANGAL G, SMYTH CL et al.: Therapeutic effect of anti-TNF-alpha antibodies in an experimental model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis. J Am Soc Nephrol. 2006; 17: 160-9.
46. KOUKOULAKI M, ABEYGUNASEKARA SC, SMITH KG, JAYNE DR: Remission of refractory hepatitis C-negative cryoglobulinaemic vasculitis after rituximab and infliximab. Nephrol Dial Transplant. 2005; 20: 213-6.
47. JOLLY M, CURRAN JJ: Infliximab-responsive uveitis and vasculitis in a patient with Takayasu arteritis. J Clin Rheumatol. 2005; 11: 213-5.
48. van der BIJL AE, ALLAART CF, Van VUGT J et al.: Rheumatoid vasculitis treated with infliximab. J Rheumatol. 2005; 32: 1607-9.
49. AL BISHRI J, LE RICHE N, POPE JE: Refractory polyarteritis nodosa successfully treated with infliximab. J Rheumatol. 2005; 32: 1371-3.
50. BOOTH A, HARPER L, HAMMAD T et al.: Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol. 2004; 15: 717-21.
51. WEISS JE, EBERHARD BA, CHOWDHURY D, GOTTLIEB BS: Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol. 2004; 31: 808-10.
52. KRAM MT, MAY LD, GOODMAN S, MOLINAS S: Behçet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case. Dis Colon Rectum. 2003; 46: 118-21.
53. AEBERLI D, OERTLE S, MAURON H et al.: Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Swiss Med Wkly. 2002; 132: 414-22.
54. BARTOLUCCI P, RAMANOELINA J, COHEN P et al.: Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford). 2002; 41: 1126-32.
55. LAMPRECHT P, VOSWINKEL J, LILIENTHAL T et al.: Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford). 2002; 41: 1303-7.
56. BIANCONE L, ORLANDO A, KOHN A et al.: Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut. 2006; 55: 228-33.
57. GEBOREK P, BLADSTROM A, TURESSON C et al.: Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis. 2005; 64: 699-703.
58. STONE JH, UHLFELDER ML, HELLMANN DB et al.: Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum. 2001; 44: 1149-54.
59. SRIVASTAVA MD, ALEXANDER F, TUTHILL RJ: Immunology of cutaneous vasculitis associated with both etanercept and infliximab. Scand J Immunol. 2005; 61: 329-36.
60. DOULTON TW, TUCKER B, REARDON J, VELASCO N: Antineutrophil cytoplasmic antibody-associated necrotizing crescentic glomerulonephritis in a patient receiving treatment with etanercept for severe rheumatoid arthritis. Clin Nephrol. 2004; 62: 234-8.
61. JARRETT SJ, CUNNANE G, CONAGHAN PG et al.: Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol 2003; 30: 2287-91.
62. RICHETTE P, DIEUDE P, DAMIANO J et al.: Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis. J Rheumatol. 2004; 31: 2079-81.
63. MOHAN N, EDWARDS ET, CUPPS TR et al.: Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol. 2004; 31: 1955-8.
64. MOR A, BINGHAM C, III, BARISONI L et al.: Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. J Rheumatol. 2005; 32: 740-3.
65. RAZA K, CARRUTHERS DM, STEVENS R et al.: Infliximab leads to a rapid but transient improvement in endothelial function in patients with primary systemic vasculitis. Ann Rheum Dis. 2005.